158 related articles for article (PubMed ID: 38582286)
21. A multicentre, multinational, prospective, observational registry study of defibrotide in patients diagnosed with veno-occlusive disease/sinusoidal obstruction syndrome after haematopoietic cell transplantation: an EBMT study.
Mohty M; Battista ML; Blaise D; Calore E; Cesaro S; Maximova N; Perruccio K; Renard C; Wynn R; Zecca M; Labopin M; Hanvesakul R; Amber V; Ryan RJ; Lawson S; Ciceri F
Bone Marrow Transplant; 2021 Oct; 56(10):2454-2463. PubMed ID: 34059801
[TBL] [Abstract][Full Text] [Related]
22. Analysis of Time to Complete Response after Defibrotide Initiation in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation.
Richardson PG; Smith AR; Kernan NA; Lehmann L; Ryan RJ; Grupp SA
Transplant Cell Ther; 2021 Jan; 27(1):88.e1-88.e6. PubMed ID: 32950693
[TBL] [Abstract][Full Text] [Related]
23. Association Between the Magnitude of Intravenous Busulfan Exposure and Development of Hepatic Veno-Occlusive Disease in Children and Young Adults Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation.
Bognàr T; Bartelink IH; Egberts TCG; Rademaker CMA; Versluys AB; Slatter MA; Kletzel M; Nath CE; Cuvelier GDE; Savic RM; Dvorak C; Long-Boyle JR; Cowan MJ; Bittencourt H; Bredius RGM; Güngör T; Shaw PJ; Ansari M; Hassan M; Krajinovic M; Hempel G; Marktel S; Chiesa R; Théoret Y; Lund T; Orchard PJ; Wynn RF; Boelens JJ; Lalmohamed A
Transplant Cell Ther; 2022 Apr; 28(4):196-202. PubMed ID: 35065280
[TBL] [Abstract][Full Text] [Related]
24. Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease.
Kayser S; Sartor C; Giglio F; Bruno A; Webster J; Chiusolo P; Saraceni F; Guerzoni S; Pochintesta L; Borlenghi E; Marconi G; Zacheo I; Cerrano M; Salutari P; Restuccia F; Abbenante M; Levis MJ; Schlenk RF; Papayannidis C
Haematologica; 2024 May; 109(5):1385-1392. PubMed ID: 38058184
[TBL] [Abstract][Full Text] [Related]
25. The use of defibrotide in blood and marrow transplantation.
Richardson PG; Carreras E; Iacobelli M; Nejadnik B
Blood Adv; 2018 Jun; 2(12):1495-1509. PubMed ID: 29945939
[TBL] [Abstract][Full Text] [Related]
26. Hepatic veno-occlusive disease/sinusoidal obstruction syndrome after hematopoietic stem cell transplantation for thalassemia major: incidence, management, and outcome.
Lai X; Liu L; Zhang Z; Shi L; Yang G; Wu M; Huang R; Liu R; Lai Y; Li Q
Bone Marrow Transplant; 2021 Jul; 56(7):1635-1641. PubMed ID: 33608657
[TBL] [Abstract][Full Text] [Related]
27. Molecular Advances in Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease.
Mavrikou I; Chatzidimitriou D; Skoura L; Nikolousis E; Sakellari I; Gavriilaki E
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982695
[TBL] [Abstract][Full Text] [Related]
28. The Prophylaxis of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome With Defibrotide After Hematopoietic Stem Cell Transplantation in Children: Single Center Experience.
Karagun BS; Akbas T; Erbey F; Sasmaz İ; Antmen B
J Pediatr Hematol Oncol; 2022 Jan; 44(1):e35-e39. PubMed ID: 34966102
[TBL] [Abstract][Full Text] [Related]
29. Predicting sinusoidal obstruction syndrome after allogeneic stem cell transplantation with the EASIX biomarker panel.
Jiang S; Penack O; Terzer T; Schult D; Majer-Lauterbach J; Radujkovic A; Blau IW; Bullinger L; Müller-Tidow C; Dreger P; Luft T
Haematologica; 2021 Feb; 106(2):446-453. PubMed ID: 31974195
[TBL] [Abstract][Full Text] [Related]
30. Real-world use of defibrotide for veno-occlusive disease/sinusoidal obstruction syndrome: the DEFIFrance Registry Study.
Mohty M; Blaise D; Peffault de Latour R; Labopin M; Bourhis JH; Bruno B; Ceballos P; Detrait M; Gandemer V; Huynh A; Izadifar-Legrand F; Jubert C; Labussière-Wallet H; Lebon D; Maury S; Paillard C; Pochon C; Renard C; Rialland F; Schneider P; Sirvent A; Asubonteng K; Guindeuil G; Yakoub-Agha I; Dalle JH
Bone Marrow Transplant; 2023 Apr; 58(4):367-376. PubMed ID: 36564486
[TBL] [Abstract][Full Text] [Related]
31. A Systematic Review and Meta-Analysis of Studies of Defibrotide Prophylaxis for Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome.
Corbacioglu S; Topaloglu O; Aggarwal S
Clin Drug Investig; 2022 Jun; 42(6):465-476. PubMed ID: 35594010
[TBL] [Abstract][Full Text] [Related]
32. Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma.
Abate ME; Paioli A; Cammelli S; Cesari M; Longhi A; Palmerini E; Ferrari S; Carretta E; Picci P; Piscaglia F
Bone Marrow Transplant; 2018 May; 53(5):591-599. PubMed ID: 29335623
[TBL] [Abstract][Full Text] [Related]
33. Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome.
Kernan NA; Grupp S; Smith AR; Arai S; Triplett B; Antin JH; Lehmann L; Shore T; Ho VT; Bunin N; Iacobelli M; Liang W; Hume R; Tappe W; Soiffer R; Richardson P
Br J Haematol; 2018 Jun; 181(6):816-827. PubMed ID: 29767845
[TBL] [Abstract][Full Text] [Related]
34. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation in adult patients: Diagnosis, incidence, prophylaxis, and treatment.
Özkan HA; Özkan SG
Transfus Apher Sci; 2022 Feb; 61(1):103372. PubMed ID: 35101376
[TBL] [Abstract][Full Text] [Related]
35. Defibrotide for the management of sinusoidal obstruction syndrome in patients who undergo haemopoietic stem cell transplantation.
Coutsouvelis J; Avery S; Dooley M; Kirkpatrick C; Spencer A
Cancer Treat Rev; 2016 Nov; 50():200-204. PubMed ID: 27721142
[TBL] [Abstract][Full Text] [Related]
36. Role of plasminogen activator inhibitor-1 (PAI-1) levels in the diagnosis of BMT-associated hepatic veno-occlusive disease and monitoring of subsequent therapy with defibrotide (DF).
Kaleelrahman M; Eaton JD; Leeming D; Bowyer K; Taberner D; Chang J; Scarffe JH; Chopra R
Hematology; 2003 Apr; 8(2):91-5. PubMed ID: 12745658
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness analysis of defibrotide in the treatment of patients with severe veno-occlusive disease/sinusoidal obstructive syndrome with multiorgan dysfunction following hematopoietic cell transplantation in Spain.
Carcedo Rodriguez D; Artola Urain T; Chinea Rodriguez A; García Torres E; González Vicent M; Gutiérrez García G; Regueiro García A; Calvo Hidalgo M; Villacampa A
J Med Econ; 2021; 24(1):628-636. PubMed ID: 33858278
[TBL] [Abstract][Full Text] [Related]
38. Pooled analysis of Day 100 survival for defibrotide-treated patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome and ventilator or dialysis dependence following haematopoietic cell transplantation.
Richardson PG; Smith AR; Kernan NA; Lehmann L; Soiffer RJ; Ryan RJ; Tappe W; Grupp S
Br J Haematol; 2020 Aug; 190(4):583-587. PubMed ID: 32157682
[TBL] [Abstract][Full Text] [Related]
39. Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results From the International Compassionate-Use Program.
Corbacioglu S; Carreras E; Mohty M; Pagliuca A; Boelens JJ; Damaj G; Iacobelli M; Niederwieser D; Olavarría E; Suarez F; Ruutu T; Verdonck L; Hume R; Nejadnik B; Lai C; Finetto G; Richardson P
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1874-1882. PubMed ID: 27397724
[TBL] [Abstract][Full Text] [Related]
40. Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome.
Corbacioglu S; Jabbour EJ; Mohty M
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1271-1280. PubMed ID: 30797942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
